Axitinib Tablets 1 mg
Axishil 1mg Tablet
Axishil 1mg Tablet is an anti-cancer medication. Axishil 1mg Tablet is used in the treatment of kidney cancer.
Axishil 1mg Tablet Composition :-
Axishil 1mg Tablet combination of : Axitinib 1mg.
Axitinib is a selective tyrosine kinase inhibitor.
Axishil 1mg Tablet Uses :-
Axishil 1mg Tablet is used for the treatment of adult patients with advanced renal cell carcinoma ( Renal cell carcinoma (RCC) is a type of cancer that begins in the cells of the kidney ) that has relapsed after failure of prior treatment with sunitinib or cytokines.
Axishil 1mg Tablet Dosage :-
Axishil 1mg Tablet is treated by a doctor experienced in the use of anticancer therapies.
Axishil 1mg Tablet is for oral use. Axishil 1mg Tablet is taken orally twice daily for about 12 hours with or without food.
Axishil 1mg Tablet should be swallowed whole with a glass of water.
The recommended dose of axitinib is 5 mg twice daily.
Axishil 1mg Tablet Side-effects :-
Common side effects of Axishil 1mg Tablet
• Diarrhea,
• Vomiting,
• Nausea,
• Abdominal pain,
• Constipation,
• Stomatitis,
• Indigestion,
• Headache,
• Cough,
• Difficult or artificial breathing,
• Haemorrhage,
• Hypertension,
• Loss of taste or loss of taste,
• Hypothyroidism,
• Decreased appetite,
• Dysphonia,
• Palmar-plantar erythrodysaesthesia (hand-foot syndrome),
• Rash,
• Dry skin,
• Joint pain,
• Proteinuria ( protein in urine ),
• Pain in extremity,
• Fatigue,
• Mucosal inflammation,
• Weight decreased,
• Decreased muscle strength,
If you undergo any side-effects, inform to your doctor.
How Axishil 1mg Tablet Works :-
Axishil 1mg Tablet contain Axitinib.
Axitinib is a selective tyrosine kinase inhibitor.
Tyrosine kinase inhibitors selectively inhibit vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). In this way axitinib inhibits angiogenesis, metastases and tumor growth.
Thus, Axishil 1mg Tablet treat to of kidney cancer.
Precautions & Warnings :-
Specific safety events should be monitored prior to initiation, and periodically during treatment with axitinib.
• Allergy :
Axishil 1mg Tablet is not recommended for use in patients with known history of allergy to the ingredients Axitinib present in it or any other inactive ingredients present in it.
• The safety and efficacy of Inlyta in children and adolescents below 18 years of age have not been established. No data is available.
• Pregnancy :
There are no data available regarding the use of axitinib in pregnant women. Based on the pharmacological properties of axitinib, it may cause fetal harm when administered to a pregnant woman. Studies in animals have shown reproductive toxicity, including malformations, so do not use axitinib during pregnancy unless the woman's clinical condition requires treatment with this drug.
• Women of childbearing potential should use effective contraception during and for 1 week after treatment.
• Breast feeding :
Axishil 1mg Tablet should not be used during breast-feeding because it is still unknown whether axitinib is excreted in human milk.
• Fertility :
Based on non-clinical findings that axitinib has the potential to reduce fertility in humans.
• Overdose :
There is no specific treatment in case of axitinib overdose.
• Events of Cardiac Failure :
In clinical studies with axitinib in patients with renal cell carcinoma (RCC), the incidence of heart failure (including heart failure, congestive heart failure, cardiopulmonary failure, left ventricular dysfunction, decreased ejection fraction, and right ventricular failure) Events happen.
• High blood Pressure :
In clinical studies with axitinib in patients with renal cell carcinoma (RCC), the incidence of hypertension was reported very commonly.
thyroid dysfunction
In clinical studies with axitinib in patients with RCC, incidences of hypothyroidism and hyperthyroidism were reported.
Periodic thyroid monitoring should be performed upon initiation of treatment with axitinib.
• Arterial Embolic & Thrombotic Events :
Axishil 1mg Tablet should be used with caution in patients with arterial embolic and thrombotic events who are at risk for these events or in patients with a history of these events.
• Venous Embolic & Thrombotic Events :
Axishil 1mg Tablet should be used with caution in patients with venous embolic and thrombotic events (including pulmonary embolism, deep vein thrombosis, and retinal vein occlusion/thrombosis) patients who are at increased risk of these events.
There have been no studies of axitinib in patients with a venous embolic or thrombotic event within the past 6 months.
• Elevation of Hemoglobin or Hematocrit :
An increase in hemoglobin or hematocrit, an increase in red blood cell mass, may occur during treatment with axitinib.
An increase in red blood cell mass increases the risk of embolic and thrombotic events.
• Aneurysm & Arterial Dissection :
Prior to initiating treatment with axitinib, patients with risk factors such as high blood pressure or a history of aneurysm should be cautious about the use of VEGF pathway inhibitors in patients with or without high blood pressure due to the formation of aneurysms and/or arterial dissection. can promote.
• Gastrointestinal Perforation & Fistula Formation :
Gastrointestinal perforation and fistula have been reported in clinical studies with axitinib, so symptoms of gastrointestinal perforation or fistula should be monitored periodically during treatment with axitinib.
• Wound Healing Complications :
There are no formal studies of the effect of axitinib on wound healing. Treatment with axitinib should be discontinued at least 24 hours before surgery. Axishil 1mg Tablet treatment is initiated upon clinical judgment of wound healing after surgery.
• Posterior reversible encephalopathy syndrome (PRES) :
In clinical studies with axitinib, the incidence of PRES may be
Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder that can cause headache, seizures, lethargy, confusion, blindness, other visual, neurological disturbances, and mild to severe hypertension.
Patients with symptoms of posterior reversible encephalopathy syndrome (PRES) should temporarily discontinue axitinib. The safety of restarting axitinib treatment in patients who previously experienced symptoms of posterior reversible encephalopathy syndrome (PRES) is not known.
• Proteinuria :
Monitoring of proteinuria is recommended before initiating treatment with axitinib and periodically for proteinuria. Patients who develop moderate to severe proteinuria may need to reduce the dose. Treatment with axitinib should be discontinued if the patient develops nephrotic syndrome.
• Liver Related Adverse Reactions :
In a controlled clinical study with axitinib for the treatment of patients with renal cell carcinoma (RCC), liver-related adverse reactions may have occurred. Such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood bilirubin etc.
Liver function tests should be monitored prior to initiation of treatment with axitinib and periodically.
• Hepatic Impairment :
Axishil 1mg Tablet has not been studied in patients with severe hepatic impairment. And dose reduction may be recommended when administering axitinib to patients with moderate hepatic impairment.
• Elderly :
Elderly patients with renal cell carcinoma (RCC) do not require any dose adjustments based on age.
• Interaction with Medicine :
If you are taking some medicine such as :
Co-administration of axitinib with strong CYP3A4/5 inhibitors (such as ketoconazole, itraconazole, clarithromycin, erythromycin, nefazodone, nelfinavir, ritonavir, atazanavir, indinavir, saquinavir, and telithromycin) may increase axitinib plasma concentrations.
• Grapefruit Juice :
Grapefruit juice may also increase plasma concentrations of axitinib. Co-administration of axitinib with certain drugs such as rifampicin, carbamazepine, rifabutin, rifapentin, dexamethasone, phenytoin, and phenobarbital may reduce the plasma concentrations of axitinib.
Axishil 1mg Tablet Mfg By :-
Shilpa Medicare Ltd
Axishil 1mg Tablet Price :-
MRP ₹ =
Axishil 1mg Tablet Storage :-
Axishil 1mg Tablet store at a temperature not exceeding 30°C.
Classification :-
Drug Name : Axitinib,
Therapeutics Indiaction : Treatment of kidney cancer.